D-cycloserine/ lurasidone (NRX-101)
Small molecule
Evidence outlook · registrational
Bipolar Depression: topline reported 2024-04-30
Its supporting mid-stage studies have completed. The sponsor reported topline results on 2024-04-30 (NRX-101 vs lurasidone Phase 2b/3 (NCT03395392) missed its primary endpoint). The announcement is listed under Regulatory events.
Also in development:Major Depressive Disorder · Phase 2/3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
SBD-ASIB NCT03396068 · Bipolar Depression Registry: NCT03396068 | 3 | MADRS-10 (Six weeks) 2024-12-31 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (1)
What this study did
Phase 2/3 (3)
What this study did
What this study did
What this study did
Phase 2 (2)
What this study did
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Bipolar Depression: Phase 3. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| D-Cycloserine / Lurasidone (NRX-101): this drug | Phase 3 | Small molecule | NMDA receptor (glycine site) + dopamine/5-HT receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Cariprazine (Vraylar) | Approved | Small molecule | Dopamine D3/D2 receptor (partial agonist) | not yet graded | No reviewed efficacy summary in this indication | |
| Lumateperone (Caplyta) | Approved | Small molecule | Serotonin 5-HT2A / dopamine D1-D2 receptor | not yet graded | No reviewed efficacy summary in this indication | |
| Lurasidone | Approved | Small molecule | Dopamine D2/D3 receptor + 5-HT7 receptor, Dopamine D2 and serotonin 5-HT2A receptors (antagonist) | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-932 | Phase 1(overall) | Small molecule | Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist), Dopamine D3/D2 and serotonin 5-HT1A receptors (partial agonist) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(2 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow D-cycloserine/lurasidone (NRX-101) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent